Dr. John Cush RheumNow
5 years 1 month ago
European Commission has approved bimekizumab (Bimzelx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis. Bimekizumab is a dual IL-17 inhibitor (IL-17A and IL-17F). https://t.co/viRNbx2cbt
Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.
Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).
Dr. John Cush RheumNow
5 years 1 month ago
Most recent numbers from the CDC - The agency said 202,041,893 people had received at least one dose while 171,367,657 people are fully vaccinated as of Tuesday. https://t.co/3rp7QMt84y
Dr. John Cush RheumNow
5 years 1 month ago
Safety study of 97 AAV (72 GPA, 25 MPA) pts Rx with Rituxan, median 8 infusions, followed median 3.9 yrs (0.05–4.32). Serious Risks (per 100 Pt-Yrs): serious infections 7.11, cardiac events 5.0, & vascular events 2.37. No deaths related to RTX. https://t.co/WLMQoq79gd
Dr. John Cush RheumNow
5 years 1 month ago
Psoriasis Prevalence in adults in the United States is 3.0%, indicating that more than 7.5 million adults 20 years or older have psoriasis. Most common in non-Hispanic White individuals; prevalence has not significantly changed since 2003. https://t.co/3yrlPu1GGi
Dr. John Cush RheumNow
5 years 1 month ago
New download available!
Cytokine Storm Overview
https://t.co/XRlx3OJDeR https://t.co/jq9ZJVx5zH
Dr. John Cush RheumNow
5 years 1 month ago
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA).
https://t.co/szl5L7DGJG https://t.co/yxoEquyLjP
Dr. John Cush RheumNow
5 years 1 month ago
Rheums--have a question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/wzNmOzH4VE https://t.co/QJn6Uo3lbM
Dr. John Cush RheumNow
5 years 1 month ago
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa
Dr. John Cush RheumNow
5 years 1 month ago
Watch Now:
Using Vitamin D in RA
https://t.co/QXYVsa5jzP https://t.co/J9zxOUVRVY
Dr. John Cush RheumNow
5 years 1 month ago
Comprehensive, full read overview of (European EADV) S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1 (classification, Dx, activity) & Part 2 (Treatment) https://t.co/puBCr8VO1I https://t.co/rZKDEsvDzr
Today, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine, manufactured by Pfizer-BioNTech COVID-19 the vaccine, now marketed as Comirnaty (koe-mir’-na-tee), is approved for the prevention of COVID-19 disease in individuals 16 years of age and older.
This long-awaited approval is the result of a Priority Review granted by the FDA.
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA).
Dr. John Cush RheumNow
5 years 1 month ago
Breakthrough infections: As of Aug. 9, almost 74% of the 8,054 vaccinated people that were hospitalized with COVID-19 were above the age of 65, according to the U.S. Centers for Disease Control and Prevention. ~20% of those cases ended in deaths https://t.co/jaSmKv5pPS

